
Beyond Drug Discovery: The Nanotechnology Molecular Optimization (NMO) Benchmark
Researchers have introduced NMO, a benchmark that redirects generative molecular design away from pharmaceutical proxy metrics toward quantum-grounded materials science targets. The work exposes a critical gap in current ML evaluation: models trained on drug-discovery datasets excel at narrow leaderboard tasks but fail to generalize to structurally different domains. By replacing heuristic oracles with quantum simulations and enforcing scientific rigor over benchmark gaming, NMO signals a broader shift in how the ML community should validate models against real-world discovery constraints rather than synthetic proxies. This matters for anyone building or deploying molecular AI outside pharma.62




























